TP53 and ovarian cancer: SLP-p53® has also been tested as part of the combination therapy with PegIntron (IFN-α) alongside gemcitabine chemotherapy in patients with platinum-resistant ovarian cancer, reporting strong specific vaccine-induced p53-specific T-cell responses [24].